Objective: To elucidate the relation between human tissue factor pathwayinhibitor-2 (TFPI-2) expression and ovarian tumor migration and invasion. Methods: Human TFPI-2expression vector pBos-Cite-neo/TFPI-2 was transfe...Objective: To elucidate the relation between human tissue factor pathwayinhibitor-2 (TFPI-2) expression and ovarian tumor migration and invasion. Methods: Human TFPI-2expression vector pBos-Cite-neo/TFPI-2 was transfected into ovarian tumor cells line A2780- Afterthe transfected cells were selected by G418, transfected and nontransfected cells were screened forTFPI-2 mRNA and protein by reverse transcription-polymerase chain reaction and Western blotanalysis, respectively. The number of transfected or nontransfected cells passing through membraneof Boyden chamber was counted as the basis assessing tumor cells migratory and invasive behaviors.Results: Expression of mRNA and protein of TFPI-2 was detectable in transfected cells. In invasionassay, the number of TFPI-2-expressing cells to traverse a Matrigel-coated membrane was obviouslydecreased compared with that of nonexpressing cells (59.3±6.5 vs 109.7±5.5, P 【 0.01); While inmigration assay, no significant difference through a noncoated membrane was observed amongtransfected and nontransfected cells (114.7±8.6 vs 127.3±7.1, P 】 0.05). Conclusion: Expression ofTFPI-2 may strongly inhibit the invasive ability of ovarian tumor cells in vitro, but has no effecton the migratory ability which provides an experimental basis for genotherapy of human ovariantumor.展开更多
目的观察大剂量甲氨蝶呤(HDMTX)治疗儿童急性淋巴细胞白血病(ALL)的不良反应,探讨不良反应影响因素。方法 32例ALL患儿接受HDMTX治疗共102例次,观察治疗不良反应,并分析响因素。结果 HDMTX治疗中的不良反应为骨髓抑制(68.6%)、口腔黏膜...目的观察大剂量甲氨蝶呤(HDMTX)治疗儿童急性淋巴细胞白血病(ALL)的不良反应,探讨不良反应影响因素。方法 32例ALL患儿接受HDMTX治疗共102例次,观察治疗不良反应,并分析响因素。结果 HDMTX治疗中的不良反应为骨髓抑制(68.6%)、口腔黏膜损害(70.6%)、胃肠道反应(55.9%)、肝功能损害(33.0%)、感染(31.4%)及皮肤损害(16.7%)。治疗后42 h甲氨蝶呤(MTX)血浆浓度越高,越容易发生口腔黏膜损害、胃肠道反应(P=0.003、0.003)。治疗后66 h MTX药物排泄延迟的患儿易发生颅内及血行播散感染等特殊部位的感染(P=0.030)。不同性别患儿口腔黏膜损害及胃肠道反应发生情况有统计学差异(P均<0.05),不同年龄患儿皮肤损害发生情况有统计学差异(P=0.020),不同临床分型、MTHFR C677T基因型各不良反应的发生情况无统计学差异(P均>0.05)。结论 HDMTX治疗的不良反应为骨髓抑制、口腔黏膜损害。胃肠道反应、肝功能损害、感染及皮肤损害,口腔黏膜损害、胃肠道反应发生与治疗后42 h MTX血浆浓度及性别有关,颅内及血行播散感染等特殊部位感染发生与66 h MTX浓度有关,皮肤损害发生与患儿年龄有关。展开更多
文摘Objective: To elucidate the relation between human tissue factor pathwayinhibitor-2 (TFPI-2) expression and ovarian tumor migration and invasion. Methods: Human TFPI-2expression vector pBos-Cite-neo/TFPI-2 was transfected into ovarian tumor cells line A2780- Afterthe transfected cells were selected by G418, transfected and nontransfected cells were screened forTFPI-2 mRNA and protein by reverse transcription-polymerase chain reaction and Western blotanalysis, respectively. The number of transfected or nontransfected cells passing through membraneof Boyden chamber was counted as the basis assessing tumor cells migratory and invasive behaviors.Results: Expression of mRNA and protein of TFPI-2 was detectable in transfected cells. In invasionassay, the number of TFPI-2-expressing cells to traverse a Matrigel-coated membrane was obviouslydecreased compared with that of nonexpressing cells (59.3±6.5 vs 109.7±5.5, P 【 0.01); While inmigration assay, no significant difference through a noncoated membrane was observed amongtransfected and nontransfected cells (114.7±8.6 vs 127.3±7.1, P 】 0.05). Conclusion: Expression ofTFPI-2 may strongly inhibit the invasive ability of ovarian tumor cells in vitro, but has no effecton the migratory ability which provides an experimental basis for genotherapy of human ovariantumor.
文摘目的观察大剂量甲氨蝶呤(HDMTX)治疗儿童急性淋巴细胞白血病(ALL)的不良反应,探讨不良反应影响因素。方法 32例ALL患儿接受HDMTX治疗共102例次,观察治疗不良反应,并分析响因素。结果 HDMTX治疗中的不良反应为骨髓抑制(68.6%)、口腔黏膜损害(70.6%)、胃肠道反应(55.9%)、肝功能损害(33.0%)、感染(31.4%)及皮肤损害(16.7%)。治疗后42 h甲氨蝶呤(MTX)血浆浓度越高,越容易发生口腔黏膜损害、胃肠道反应(P=0.003、0.003)。治疗后66 h MTX药物排泄延迟的患儿易发生颅内及血行播散感染等特殊部位的感染(P=0.030)。不同性别患儿口腔黏膜损害及胃肠道反应发生情况有统计学差异(P均<0.05),不同年龄患儿皮肤损害发生情况有统计学差异(P=0.020),不同临床分型、MTHFR C677T基因型各不良反应的发生情况无统计学差异(P均>0.05)。结论 HDMTX治疗的不良反应为骨髓抑制、口腔黏膜损害。胃肠道反应、肝功能损害、感染及皮肤损害,口腔黏膜损害、胃肠道反应发生与治疗后42 h MTX血浆浓度及性别有关,颅内及血行播散感染等特殊部位感染发生与66 h MTX浓度有关,皮肤损害发生与患儿年龄有关。
